Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
mepolizumab (681) 681
index medicus (458) 458
asthma (433) 433
humans (411) 411
immunology (252) 252
allergy (234) 234
respiratory system (193) 193
asthma - drug therapy (167) 167
double-blind (167) 167
inflammation (156) 156
eosinophils (139) 139
male (136) 136
female (135) 135
omalizumab (134) 134
exacerbations (133) 133
adult (126) 126
asthma - immunology (114) 114
abridged index medicus (102) 102
cytokines (101) 101
patients (99) 99
biomarkers (95) 95
middle aged (95) 95
anti-asthmatic agents - therapeutic use (94) 94
severe eosinophilic asthma (94) 94
animals (90) 90
monoclonal antibodies (89) 89
benralizumab (87) 87
il-5 (87) 87
leukocytes (87) 87
eosinophilic asthma (85) 85
safety (84) 84
severe asthma (82) 82
eosinophils - immunology (79) 79
allergy and immunology (78) 78
efficacy (78) 78
eosinophilia (77) 77
monoclonal-antibody (77) 77
persistent asthma (74) 74
antibodies, monoclonal - therapeutic use (72) 72
interleukin-5 (72) 72
severity of illness index (72) 72
antibodies, monoclonal, humanized - therapeutic use (71) 71
medicine, general & internal (71) 71
phenotypes (70) 70
reslizumab (70) 70
studies (69) 69
drug therapy (68) 68
eosinophil (67) 67
hypereosinophilic syndrome (67) 67
treatment outcome (67) 67
care and treatment (66) 66
corticosteroids (65) 65
asthma - physiopathology (63) 63
pharmacology & pharmacy (63) 63
placebo (63) 63
disease (61) 61
analysis (60) 60
allergies (59) 59
asthma - diagnosis (59) 59
clinical trials (59) 59
multicenter (59) 59
interleukin-5 - immunology (55) 55
phenotype (55) 55
adults (54) 54
inhaled corticosteroids (53) 53
medical research (53) 53
interleukin 5 (52) 52
therapy (52) 52
children (51) 51
interleukin-5 - antagonists & inhibitors (51) 51
leukocyte count (50) 50
sputum (50) 50
research (48) 48
mepolizumab therapy (47) 47
respiratory tract diseases (47) 47
airway inflammation (46) 46
cluster-analysis (46) 46
eosinophilic esophagitis (46) 46
quality of life (46) 46
adolescent (45) 45
aged (44) 44
article (44) 44
young adult (44) 44
asthma - pathology (43) 43
asthma - therapy (43) 43
critical care medicine (43) 43
eosinophils - pathology (43) 43
immunoglobulin e (43) 43
antibody (40) 40
disease progression (40) 40
interleukins (40) 40
child (39) 39
expression (39) 39
receptor (39) 39
biologics (38) 38
drug dosages (38) 38
medicine, research & experimental (38) 38
asthma - metabolism (37) 37
blood (36) 36
health aspects (36) 36
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (708) 708
German (22) 22
French (16) 16
Spanish (5) 5
Korean (2) 2
Russian (2) 2
Croatian (1) 1
Italian (1) 1
Japanese (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype
by Gupta, Atul and Ikeda, Masanori and Geng, Bob and Azmi, Jay and Price, Robert G and Bradford, Eric S and Yancey, Steven W and Steinfeld, Jonathan
The Journal of allergy and clinical immunology, ISSN 0091-6749, 08/2019
Mepolizumab is approved for patients with severe asthma with an eosinophilic phenotype aged ≥12 (US) or ≥6 (EU) years, but its long-term use in children aged... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Eosinophil apoptosis-inducing drugs risk worsening rather than resolving asthma Reply
by Bochner, BS and Kiwamoto, T and Katoh, T and Zhu, Z and Tiemeyer, M
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ISSN 0091-6749, 06/2015, Volume 135, Issue 6, pp. 1662 - 1663
MEPOLIZUMAB | ALLERGY | RESLIZUMAB | IMMUNOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Current treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
by Moosig, F and Holle, J
Zeitschrift fur Rheumatologie, ISSN 0340-1855, 2019
Immunosuppression | Prognosis | Vasculitis | Mepolizumab | Biologicals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Case study: A Combination of Mepolizumab and Omaluzimab injections for severe asthma
by Dedaj, Rejmon and Unsel, Lindie
Journal of Asthma, ISSN 0277-0903, 05/2019, Volume 56, Issue 5, pp. 473 - 474
A Combination of Mepolizumab and Omaluzimab injections for severe asthma. Introduction. Patients with severe persistent asthma account for a large proportion... 
severe asthma | omalizumab | mepolizumab | ALLERGY | RESPIRATORY SYSTEM
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Do eosinophils contribute to oxidative stress in mild asthma?
by Groot, Linsey E. S and Sabogal Piñeros, Yanaika S and Bal, Suzanne M and Pol, Marianne A and Hamann, Jörg and Sterk, Peter J and Kulik, Wim and Lutter, René
Clinical & Experimental Allergy, ISSN 0954-7894, 06/2019, Volume 49, Issue 6, pp. 929 - 931
MEPOLIZUMAB | IMMUNOLOGY | ALLERGY | OXIDANTS | Asthma | Oxidative stress | Leukocytes (eosinophilic) | Eosinophils
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Fevipiprant, a prostaglandin D-2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial
by Gonem, S and Berair, R and Singapuri, A and Hartley, R and Laurencin, MFM and Bacher, G and Holzhauer, B and Bourne, M and Mistry, V and Pavord, ID and Mansur, AH and Wardlaw, AJ and Siddiqui, SH and Kay, RA and Brightling, CE
LANCET RESPIRATORY MEDICINE, ISSN 2213-2600, 09/2016, Volume 4, Issue 9, pp. 699 - 707
Background Eosinophilic airway inflammation is often present in asthma, and reduction of such inflammation results in improved clinical outcomes. We... 
APOPTOSIS | TH2 CELLS | MEPOLIZUMAB | EFFICACY | CRTH2 ANTAGONIST | RESPIRATORY SYSTEM | EXACERBATIONS | VALIDATION | T(H)2 CELLS | QUESTIONNAIRE | OC000459 | CRITICAL CARE MEDICINE
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Poor control of asthma symptoms with interleukin-5 inhibitors in four patients with aspirin-exacerbated respiratory disease
by Eid, Ryan C and Wudneh, Eden and Zahid, Soombal and Cahill, Katherine and Jerschow, Elina
Annals of Allergy, Asthma & Immunology, ISSN 1081-1206, 10/2019
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Eosinophile Granulomatose mit Polyangiitis (Churg-Strauss-Syndrom)
by Jerrentrup, A and Muller, T and Mariss, J and Dylla, S
INTERNIST, ISSN 0020-9554, 05/2018, Volume 59, Issue 5, pp. 497 - 504
MEDICINE, GENERAL & INTERNAL | MEPOLIZUMAB
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text External validation of blood eosinophils, FENO and serum periostin as surrogates for sputum eosinophils in asthma
by Wagener, A H and de Nijs, S B and Lutter, R and Sousa, A R and Weersink, E J M and Bel, E H and Sterk, P J
Thorax, ISSN 0040-6376, 02/2015, Volume 70, Issue 2, pp. 115 - 120
Background Monitoring sputum eosinophils in asthma predicts exacerbations and improves management of asthma. Thus far, blood eosinophils and FENO show... 
NITRIC-OXIDE LEVELS | MEPOLIZUMAB | BIOMARKER | AIRWAY INFLAMMATION | PHENOTYPES | INTERLEUKIN-5 | Asthma | Eosinophil Biology | COUNTS | RESPIRATORY SYSTEM | EXACERBATIONS | PLACEBO-CONTROLLED TRIAL | CORTICOSTEROIDS | Care and treatment | Inflammation | Diagnosis | Health aspects | Eosinophils | Studies | Biomarkers | Population | Accuracy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
by FitzGerald, JM and Bleecker, ER and Nair, P and Korn, S and Ohta, K and Lommatzsch, M and Ferguson, GT and Busse, WW and Barker, P and Sproule, S and Gilmartin, G and Werkstrom, V and Aurivillius, M and Goldman, M and CALIMA Study Investigators
LANCET, ISSN 0140-6736, 10/2016, Volume 388, Issue 10056, pp. 2128 - 2141
Background Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor a monoclonal antibody that induces direct, rapid, and nearly complete... 
MEDICINE, GENERAL & INTERNAL | MEPOLIZUMAB | EFFICACY | SAFETY | DREAM | ADULTS | PERSISTENT ASTHMA | MEDI-563 | CELL-MEDIATED CYTOTOXICITY | PREVALENCE | QUESTIONNAIRE | Medical colleges | Care and treatment | Interleukins | Clinical trials | Monoclonal antibodies | Product development | Pharmaceutical industry | Asthma | Studies | Cytokines | Questionnaires | Drug dosages | Patients | Quality of life
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Novel Treatments for Airway Disease REPLY
by Wechsler, ME and Akuthota, P and Khoury, P
NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 08/2017, Volume 377, Issue 6, pp. 597 - 598
MEDICINE, GENERAL & INTERNAL | MEPOLIZUMAB | SEVERE EOSINOPHILIC ASTHMA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Biologics for the treatment of chronic rhinosinusitis with nasal polyps - state of the art
by Ren, Lei and Zhang, Nan and Zhang, Luo and Bachert, Claus
The World Allergy Organization journal, ISSN 1939-4551, 08/2019, Volume 12, Issue 8, p. 100050
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex upper airway disease affecting up to 11% of the population of Western Europe. In these western... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Patients in the IDEAL cohort: A snapshot of severe asthma in France
by Taillé, C and Pison, C and Nocent, C and Devouassoux, G and Prud'homme, A and Gruber, A and Gunsoy, N and Albers, F
Revue des Maladies Respiratoires, ISSN 0761-8425, 02/2019, Volume 36, Issue 2, pp. 179 - 190
Introduction: This paper reports the French data from a post-hoc analysis of the international IDEAL study, which aimed to describe a recent cohort of patients... 
Observational study | Omalizumab | Severe asthma | Mepolizumab
Journal Article
Details down arrow
14. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature
by Volmer, Timm and Effenberger, Timo and Trautner, Christoph and Buhl, Roland
The European respiratory journal, ISSN 0903-1936, 10/2018, Volume 52, Issue 4
This review provides an overview of the role of long-term treatment of severe asthma with oral corticosteroids (OCS) and its associated side-effects in adults.... 
OMALIZUMAB | MEPOLIZUMAB | RESPIRATORY SYSTEM | COMPLICATIONS | QUALITY-OF-LIFE | BURDEN | ADVERSE EVENTS
Journal Article
Details down arrow
15. Full Text Molecular and clinical rationale for therapeutic targeting of interleukin‐5 and its receptor
by Molfino, N. A and Gossage, D and Kolbeck, R and Parker, J. M and Geba, G. P
Clinical & Experimental Allergy, ISSN 0954-7894, 05/2012, Volume 42, Issue 5, pp. 712 - 737
Summary Interleukin‐5 is a Th2 homodimeric cytokine involved in the differentiation, maturation, migration, development, survival, trafficking and effector... 
reslizumab | mepolizumab | interleukin‐5 receptor | eosinophils | asthma | benralizumab | interleukin‐5 | Benralizumab | Interleukin-5 receptor | Mepolizumab | Interleukin-5 | Asthma | Eosinophils | Reslizumab | CHURG-STRAUSS-SYNDROME | ACTIVATED PROTEIN-KINASE | COLONY-STIMULATING FACTOR | COMMON BETA-SUBUNIT | RANDOMIZED CONTROLLED-TRIAL | IMMUNOLOGY | REFRACTORY EOSINOPHILIC ASTHMA | interleukin-5 | OBSTRUCTIVE PULMONARY-DISEASE | ALLERGY | ANTI-IL-5 MEPOLIZUMAB THERAPY | HUMANIZED MONOCLONAL-ANTIBODY | interleukin-5 receptor | RESPIRATORY SYNCYTIAL VIRUS | Signal Transduction | Interleukin-5 - metabolism | Humans | Antibodies, Monoclonal - adverse effects | Hypersensitivity - immunology | Antibodies, Monoclonal - therapeutic use | Eosinophils - immunology | Hypersensitivity - drug therapy | Anti-Allergic Agents - therapeutic use | Animals | Interleukin-5 - antagonists & inhibitors | Anti-Allergic Agents - adverse effects | Protein Binding | Receptors, Interleukin-5 - antagonists & inhibitors | Receptors, Interleukin-5 - metabolism | Disease Models, Animal | Cytokines | Medical research | Rodents | Corticoids | Animal models | Gastrointestinal tract diseases | Leukocyte migration | Helper cells | Cytotoxicity | Lymphocytes T | Blood | Churg-Strauss syndrome | Interleukin 5 | Atopic dermatitis | Interleukin 3 | Chronic obstructive pulmonary disease | Cell survival | Immune response | Granulocyte-macrophage colony-stimulating factor | Leukocytes (eosinophilic) | Antisense oligonucleotides | Inflammation | siRNA | Eosinophilia | Side effects | Reviews | Monoclonal antibodies | Interleukin 5 receptors | Mast cells | Differentiation | Leukocytes (basophilic) | polyposis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text No Effect of Anti-Interleukin-5 Therapy (Mepolizumab) on the Atopy Patch Test in Atopic Dermatitis Patients
by Oldhoff, J.M and Darsow, U and Werfel, T and Bihari, I.C and Katzer, K and Laifaoui, J and Plötz, S and Kapp, A and Knol, E.F and Bruijnzeel-Koomen, C.A.F.M and Ring, J and de Bruin-Weller, M.S
International Archives of Allergy and Immunology, ISSN 1018-2438, 10/2006, Volume 141, Issue 3, pp. 290 - 294
Background: The atopy patch test (APT) is an in vivo model to study the induction of eczema by inhalant allergens in atopic dermatitis (AD) patients.... 
Original Paper | Anti-interleukin-5 antibody | Atopic dermatitis | Mepolizumab | Atopy patch test | Eosinophils | Skin biopsies | ECZEMA | ALLERGENS | atopy patch test | atopic dermatitis | eosinophils | IMMUNOLOGY | INTERLEUKIN-5 | ALLERGY | mepolizumab | IN-VIVO | AEROALLERGENS | anti-interleukin-5 antibody | skin biopsies | Eosinophils - drug effects | Interleukin-5 - metabolism | Cell Count | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Dermatitis, Atopic - physiopathology | Eosinophils - immunology | Antibodies, Monoclonal, Humanized | Dermatitis, Atopic - drug therapy | Interleukin-5 - antagonists & inhibitors | Treatment Failure | Dermatitis, Atopic - immunology | Adult | Female | Patch Tests | Monoclonal antibodies | Cytokines | Drug therapy | Dermatitis | Diagnostic tests
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
by Bleecker, ER and FitzGerald, JM and Chanez, P and Papi, A and Weinstein, SF and Barker, P and Sproule, S and Gilmartin, G and Aurivillius, M and Werkstrom, V and Goldman, M and SIROCCO Study Investigators and SIROCCO study investigators
LANCET, ISSN 0140-6736, 10/2016, Volume 388, Issue 10056, pp. 2115 - 2127
Background Eosinophilia is associated with worsening asthma severity and decreased lung function, with increased exacerbation frequency. We assessed the safety... 
BIOMARKERS | ALPHA MONOCLONAL-ANTIBODY | MEDICINE, GENERAL & INTERNAL | MEPOLIZUMAB | SEVERE EOSINOPHILIC ASTHMA | DREAM | DOUBLE-BLIND | ADULTS | MEDI-563 | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Anti-Asthmatic Agents - therapeutic use | Eosinophilia - blood | Humans | Middle Aged | Administration, Inhalation | Male | Adrenal Cortex Hormones - therapeutic use | Asthma - drug therapy | Disease Progression | Dose-Response Relationship, Drug | Forced Expiratory Volume | Antibodies, Monoclonal, Humanized - administration & dosage | Adolescent | Adult | Female | Aged | Adrenergic beta-Agonists - therapeutic use | Drug Therapy, Combination | Child
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Severe eosinophilic asthma: A roadmap to consensus
by Buhl, Roland and Humbert, Marc and Bjermer, Leif and Chanez, Pascal and Heaney, Liam G and Pavord, Ian and Quirce, Santiago and Virchow, Johann C and Holgate, Stephen and Djukanovic, Ratko and Chung, Kian Fan and Canonica, Walter and Papi, Alberto and Brightling, Chris and Horváth, Ildiko and Walker, Samantha and Brusselle, Guy and Backer, Vibeke and Kuna, Piotr and Bel, Elisabeth and De Llano, Luis Perez and Rabe, Klaus and Expert Grp European Consensus Meet and expert group of the European Consensus Meeting for Severe Eosinophilic Asthma
European Respiratory Journal, ISSN 0903-1936, 05/2017, Volume 49, Issue 5, pp. 1700634 - 1700634
Asthma is widely accepted as a complex heterogeneous condition with diverse pathophysiological mechanisms, clinical presentations, comorbidities, physiological... 
PLACEBO | MULTICENTER | MEPOLIZUMAB | RESPIRATORY SYSTEM | DREAM | DOUBLE-BLIND | RECEPTOR | MONOCLONAL-ANTIBODY | PHENOTYPES | BENRALIZUMAB | Leukocytes (eosinophilic) | Inflammation | Asthma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Role of Primary Necrosis/Lysis of Submucosal Eosinophils in Obese Individuals with Asthma Reply
by Brightling, CE and Desai, D
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, ISSN 1073-449X, 12/2013, Volume 188, Issue 12, pp. 1468 - 1469
MEPOLIZUMAB | SPUTUM | RESPIRATORY SYSTEM | CRITICAL CARE MEDICINE
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
by Castro, Mario, Prof and Zangrilli, James, MD and Wechsler, Michael E, Prof and Bateman, Eric D, Prof and Brusselle, Guy G, Prof and Bardin, Philip, Prof and Murphy, Kevin, MD and Maspero, Jorge F, MD and O'Brien, Christopher, MD and Korn, Stephanie, MD
Lancet Respiratory Medicine, The, ISSN 2213-2600,